Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Express Scripts
McKesson
Colorcon
Merck

Last Updated: November 30, 2022

United States: These 27 Drugs Face Patent Expirations and Generic Entry From 2022 - 2023

DrugPatentWatch® Estimated Loss of Exclusivity Dates in the United States

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "United States: These 27 Drugs Face Patent Expirations and Generic Entry From 2022 - 2023" DrugPatentWatch.com thinkBiotech, 2022 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can GOPRELTO (cocaine hydrochloride) generic drug versions launch?

Generic name: cocaine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GOPRELTO is a drug marketed by Genus Lifesciences. There are twelve patents protecting this drug. There has been litigation on patents covering GOPRELTO

The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

When can GIAPREZA (angiotensin ii acetate) generic drug versions launch?

Generic name: angiotensin ii acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2022
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GIAPREZA is a drug marketed by La Jolla Pharma. There are ten patents protecting this drug.

This drug has forty patent family members in twenty-two countries.

See drug price trends for GIAPREZA.

The generic ingredient in GIAPREZA is angiotensin ii acetate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the angiotensin ii acetate profile page.

When can NUMBRINO (cocaine hydrochloride) generic drug versions launch?

Generic name: cocaine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NUMBRINO is a drug marketed by Cody Labs Inc.

This drug has forty patent family members in twenty-two countries.

See drug price trends for NUMBRINO.

The generic ingredient in NUMBRINO is cocaine hydrochloride. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cocaine hydrochloride profile page.

When can ADVIL DUAL ACTION WITH ACETAMINOPHEN (acetaminophen; ibuprofen) generic drug versions launch?

Generic name: acetaminophen; ibuprofen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ADVIL DUAL ACTION WITH ACETAMINOPHEN is a drug marketed by Glaxosmithkline.

This drug has forty patent family members in twenty-two countries.

The generic ingredient in ADVIL DUAL ACTION WITH ACETAMINOPHEN is acetaminophen; ibuprofen. There are sixty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the acetaminophen; ibuprofen profile page.

When can NORMOCARB HF 25 (magnesium chloride; sodium bicarbonate; sodium chloride) generic drug versions launch?

Generic name: magnesium chloride; sodium bicarbonate; sodium chloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 04, 2023
Generic Entry Controlled by: United States Patent Patent 7,300,674

NORMOCARB HF 25 is a drug marketed by Dialysis Sups. There is one patent protecting this drug.

This drug has four patent family members in four countries.

The generic ingredient in NORMOCARB HF 25 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this API. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

When can CHLORAPREP ONE-STEP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 14, 2023
Generic Entry Controlled by: United States Patent Patent 7,241,065

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co. There are two patents protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

When can DEFITELIO (defibrotide sodium) generic drug versions launch?

Generic name: defibrotide sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DEFITELIO is a drug marketed by Jazz Pharms Inc. There are two patents protecting this drug.

This drug has twenty-five patent family members in sixteen countries.

See drug price trends for DEFITELIO.

The generic ingredient in DEFITELIO is defibrotide sodium. One supplier is listed for this generic product. Additional details are available on the defibrotide sodium profile page.

When can TARGINIQ (naloxone hydrochloride; oxycodone hydrochloride) generic drug versions launch?

Generic name: naloxone hydrochloride; oxycodone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2023
Generic Entry Controlled by: United States Patent Patent 9,907,793

TARGINIQ is a drug marketed by Purdue Pharma Lp. There are fifteen patents protecting this drug.

This drug has three hundred and five patent family members in forty-four countries. There has been litigation on patents covering TARGINIQ

The generic ingredient in TARGINIQ is naloxone hydrochloride; oxycodone hydrochloride. There are twelve drug master file entries for this API. Additional details are available on the naloxone hydrochloride; oxycodone hydrochloride profile page.

When can PROVAYBLUE (methylene blue) generic drug versions launch?

Generic name: methylene blue
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 08, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PROVAYBLUE is a drug marketed by Provepharm Sas.

This drug has three hundred and five patent family members in forty-four countries.

See drug price trends for PROVAYBLUE.

The generic ingredient in PROVAYBLUE is methylene blue. There are twenty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the methylene blue profile page.

When can AMTURNIDE (aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2023
Generic Entry Controlled by: United States Patent Patent 8,183,295

AMTURNIDE is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-four countries.

The generic ingredient in AMTURNIDE is aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; amlodipine besylate; hydrochlorothiazide profile page.

When can LUCEMYRA (lofexidine hydrochloride) generic drug versions launch?

Generic name: lofexidine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 16, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for LUCEMYRA
LUCEMYRA is a drug marketed by Uswm.

This drug has thirty-two patent family members in twenty-four countries.

See drug price trends for LUCEMYRA.

The generic ingredient in LUCEMYRA is lofexidine hydrochloride. Additional details are available on the lofexidine hydrochloride profile page.

When can PHEXXI (citric acid; lactic acid; potassium bitartrate) generic drug versions launch?

Generic name: citric acid; lactic acid; potassium bitartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 22, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for PHEXXI
PHEXXI is a drug marketed by Evofem Inc. There are four patents protecting this drug.

This drug has sixty-four patent family members in twenty-three countries.

See drug price trends for PHEXXI.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

When can VISTOGARD (uridine triacetate) generic drug versions launch?

Generic name: uridine triacetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

VISTOGARD is a drug marketed by Wellstat Therap. There are two patents protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in VISTOGARD is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

When can XURIDEN (uridine triacetate) generic drug versions launch?

Generic name: uridine triacetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2023
Generic Entry Controlled by: United States Patent Patent 6,258,795

XURIDEN is a drug marketed by Wellstat Therap. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the uridine triacetate profile page.

When can PHOTREXA (riboflavin 5'-phosphate sodium) generic drug versions launch?

Generic name: riboflavin 5'-phosphate sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 15, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PHOTREXA is a drug marketed by Glaukos.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in PHOTREXA is riboflavin 5'-phosphate sodium. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the riboflavin 5'-phosphate sodium profile page.

When can MOZOBIL (plerixafor) generic drug versions launch?

Generic name: plerixafor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2023
Generic Entry Controlled by: United States Patent Patent 7,897,590

MOZOBIL is a drug marketed by Genzyme. There are two patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has fifty-two patent family members in twenty-seven countries. There has been litigation on patents covering MOZOBIL

See drug price trends for MOZOBIL.

The generic ingredient in MOZOBIL is plerixafor. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the plerixafor profile page.

When can BREZTRI AEROSPHERE (budesonide; formoterol fumarate; glycopyrrolate) generic drug versions launch?

Generic name: budesonide; formoterol fumarate; glycopyrrolate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 23, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BREZTRI AEROSPHERE is a drug marketed by Astrazeneca Ab. There are eight patents protecting this drug.

This drug has one hundred and ninety-eight patent family members in thirty-three countries.

The generic ingredient in BREZTRI AEROSPHERE is budesonide; formoterol fumarate; glycopyrrolate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the budesonide; formoterol fumarate; glycopyrrolate profile page.

When can CYSTADROPS (cysteamine hydrochloride) generic drug versions launch?

Generic name: cysteamine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 19, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

CYSTADROPS is a drug marketed by Recordati Rare.

This drug has one hundred and ninety-eight patent family members in thirty-three countries.

See drug price trends for CYSTADROPS.

The generic ingredient in CYSTADROPS is cysteamine hydrochloride. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cysteamine hydrochloride profile page.

When can VYVANSE (lisdexamfetamine dimesylate) generic drug versions launch?

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 24, 2023
Generic Entry Controlled by: United States Patent Patent 7,655,630

Drug Price Trends for VYVANSE
VYVANSE is a drug marketed by Takeda Pharms Usa. There are eighteen patents protecting this drug and one Paragraph IV challenge. Six tentatively approved generics are ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-seven countries. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. One supplier is listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

When can TYZEKA (telbivudine) generic drug versions launch?

Generic name: telbivudine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 11, 2023
Generic Entry Controlled by: United States Patent Patent 6,569,837

TYZEKA is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eleven patent family members in seven countries.

The generic ingredient in TYZEKA is telbivudine. There are two drug master file entries for this API. Additional details are available on the telbivudine profile page.

When can ERAXIS (anidulafungin) generic drug versions launch?

Generic name: anidulafungin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ERAXIS is a drug marketed by Vicuron Holdings.

This drug has eleven patent family members in seven countries.

See drug price trends for ERAXIS.

The generic ingredient in ERAXIS is anidulafungin. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the anidulafungin profile page.

When can VOTRIENT (pazopanib hydrochloride) generic drug versions launch?

Generic name: pazopanib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 19, 2023
Generic Entry Controlled by: United States Patent Patent 7,105,530

VOTRIENT is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

See drug price trends for VOTRIENT.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pazopanib hydrochloride profile page.

When can SUTAB (COPACKAGED) (magnesium sulfate; potassium chloride; sodium sulfate) generic drug versions launch?

Generic name: magnesium sulfate; potassium chloride; sodium sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 10, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SUTAB (COPACKAGED) is a drug marketed by

This drug has forty patent family members in twenty-five countries.

The generic ingredient in SUTAB (COPACKAGED) is magnesium sulfate; potassium chloride; sodium sulfate. There are one hundred and forty-six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the magnesium sulfate; potassium chloride; sodium sulfate profile page.

When can XOPENEX HFA (levalbuterol tartrate) generic drug versions launch?

Generic name: levalbuterol tartrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2023
Generic Entry Controlled by: United States Patent Patent 8,765,153

Drug Price Trends for XOPENEX HFA
XOPENEX HFA is a drug marketed by Sunovion. There are two patents protecting this drug.

This drug has thirty-six patent family members in eighteen countries. There has been litigation on patents covering XOPENEX HFA

See drug price trends for XOPENEX HFA.

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. There are nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the levalbuterol tartrate profile page.

When can THALOMID (thalidomide) generic drug versions launch?

Generic name: thalidomide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 09, 2023
Generic Entry Controlled by: United States Patent Patent 7,230,012

THALOMID is a drug marketed by Celgene. There is one patent protecting this drug and three Paragraph IV challenges.

This drug has twenty-nine patent family members in nineteen countries. There has been litigation on patents covering THALOMID

See drug price trends for THALOMID.

The generic ingredient in THALOMID is thalidomide. There are eleven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the thalidomide profile page.

When can MOTEGRITY (prucalopride succinate) generic drug versions launch?

Generic name: prucalopride succinate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

Drug Price Trends for MOTEGRITY
MOTEGRITY is a drug marketed by Takeda Pharms Usa.

This drug has twenty-nine patent family members in nineteen countries.

See drug price trends for MOTEGRITY.

The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this generic product. Additional details are available on the prucalopride succinate profile page.

When can RAPIVAB (peramivir) generic drug versions launch?

Generic name: peramivir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 16, 2023
Generic Entry Controlled by: United States Patent Patent 6,562,861

RAPIVAB is a drug marketed by Biocryst. There are three patents protecting this drug.

This drug has sixty-eight patent family members in twenty-eight countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. Additional details are available on the peramivir profile page.

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Express Scripts
Medtronic
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.